

**Clinical trial results:****A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab in Combination With Chemotherapy Followed by Maintenance Therapy of Avelumab in Combination With the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in subjects With Previously Untreated Advanced Ovarian Cancer (JAVELIN Ovarian PARP 100)****Summary**

EudraCT number	2017-004456-30
Trial protocol	SK CZ HU BE GB EE HR IT
Global end of trial date	22 December 2021

Results information

Result version number	v1 (current)
This version publication date	23 December 2022
First version publication date	23 December 2022

Trial information**Trial identification**

Sponsor protocol code	B9991030
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03642132
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center , Pfizer Inc. , +1 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc. , +1 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 December 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 December 2021
Global end of trial reached?	Yes
Global end of trial date	22 December 2021
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To demonstrate that avelumab in combination with platinum-based chemotherapy followed by avelumab plus talazoparib maintenance is superior to platinum based chemotherapy plus bevacizumab followed by bevacizumab maintenance in prolonging progressive-free survival(PFS) in subjects with advanced ovarian cancer with defects in DNA damage repair (DDR+).

Protection of trial subjects:

This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of trial subjects.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 July 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	Italy: 9
Country: Number of subjects enrolled	Japan: 1
Country: Number of subjects enrolled	Korea, Republic of: 6
Country: Number of subjects enrolled	Russian Federation: 2
Country: Number of subjects enrolled	Singapore: 1
Country: Number of subjects enrolled	Taiwan: 4
Country: Number of subjects enrolled	United States: 53
Worldwide total number of subjects	79
EEA total number of subjects	12

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	49
From 65 to 84 years	30
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study. As only 11% projected enrollment was met at the time of enrollment stop, the original study endpoints are no longer applicable and/or feasible; only the Safety, PK and Immunogenicity Analysis were done and these data are included in this report.

Pre-assignment

Screening details:

A total of 104 subjects were screened. Seventy-nine subjects completed screening and were randomized in the study prior to study discontinuation. Seventy-six subjects received study treatment across the 3 arms

Period 1

Period 1 title	Chemotherapy Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Chemotherapy +Avelumab -> Avelumab + Talazoparib

Arm description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² intravenously(IV) over 3 hours followed by carboplatin area under the concentration (AUC) 5 or 6 IV over 15-60 minutes on Days 1 of each 3 week cycle for 6 cycles along with avelumab 800 mg administered IV on Day 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received avelumab 800 mg administered IV on Days 1, 15 and 29 of each 6-week cycle in combination with talazoparib 0.75 mg self-administered orally once per day. A cycle was defined as 3 weeks (21 days) in the chemotherapy period and 6 weeks (42 days) in the maintenance period, respectively.

Arm type	Experimental
Investigational medicinal product name	Avelumab (MSB0010718C) Solution for Infusion, 20 mg/mL (10 mL/vial)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received Avelumab 800 mg administered intravenously on Day 1 of each 3-week cycle for 6 cycles.

Arm title	Chemotherapy -> Talazoparib
------------------	-----------------------------

Arm description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Days 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received talazoparib 0.75 mg self-administered orally once a day, every day of each 6-week cycle.

Arm type	No intervention
No investigational medicinal product assigned in this arm	
Arm title	Chemotherapy + Bevacizumab -> Bevacizumab

Arm description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Day 1 of each 3-week cycle for 6 cycles along with Bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle beginning with Cycle 2 for adjuvant subjects, and for neoadjuvant subjects, bevacizumab was given on Day 1 of each 3-week cycle for Cycles 1, 2, 5, and 6. In maintenance period, subjects received bevacizumab 15 mg/kg administered IV on Days 1 and

22 of each 6-week cycle.

Arm type	Experimental
Investigational medicinal product name	Bevacizumab solution for intravenous infusion 400 mg/16 mL vial (Avastin)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received Bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle beginning with Cycle 2 for adjuvant subjects, and for neoadjuvant subjects, bevacizumab was given on Day 1 of each 3-week cycle for Cycles 1, 2, 5, and 6.

Number of subjects in period 1	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab
Started	32	13	34
Completed	19	8	27
Not completed	13	5	7
Consent withdrawn by subject	7	3	1
Adverse event, non-fatal	1	1	-
Study terminated by sponsor	-	-	3
Unspecified	1	-	2
Progressive disease	-	-	1
Physician's decision	4	1	-

Period 2

Period 2 title	Maintenance Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Chemotherapy +Avelumab -> Avelumab + Talazoparib

Arm description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² intravenously(IV) over 3 hours followed by carboplatin area under the concentration (AUC) 5 or 6 IV over 15-60 minutes on Days 1 of each 3 week cycle for 6 cycles along with avelumab 800 mg administered IV on Day 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received avelumab 800 mg administered IV on Days 1, 15 and 29 of each 6-week cycle in combination with talazoparib 0.75 mg self-administered orally once per day. A cycle was defined as 3 weeks (21 days) in the chemotherapy period and 6 weeks (42 days) in the maintenance period, respectively.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Avelumab (MSB0010718C) Solution for Infusion, 20 mg/mL (10 mL/vial)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received Avelumab 800 mg administered intravenously on Days 1, 15 and 29 of each 6-week cycle.

Investigational medicinal product name	Talazoparib 1mg Bottle 30 ct. (MDV 3800 Capsules)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received talazoparib 0.75 mg self-administered orally once per day.

Arm title	Chemotherapy -> Talazoparib
------------------	-----------------------------

Arm description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Days 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received talazoparib 0.75 mg self-administered orally once a day, every day of each 6-week cycle.

Arm type	Experimental
Investigational medicinal product name	Talazoparib 0.25 mg Bottle 30 ct. (MDV3800 Capsules)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received Talazoparib 0.75 mg self-administered orally once a day, every day of each 6-week cycle.

Arm title	Chemotherapy + Bevacizumab -> Bevacizumab
------------------	---

Arm description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Day 1 of each 3-week cycle for 6 cycles along with Bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle beginning with Cycle 2 for adjuvant subjects, and for neoadjuvant subjects, bevacizumab was given on Day 1 of each 3-week cycle for Cycles 1, 2, 5, and 6. In maintenance period, subjects received bevacizumab 15 mg/kg administered IV on Days 1 and 22 of each 6-week cycle.

Arm type	Experimental
Investigational medicinal product name	Bevacizumab solution for intravenous infusion 400 mg/16 mL vial (Avastin)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received Bevacizumab 15 mg/kg administered intravenously on Days 1 and 22 of each 6-week cycle.

Number of subjects in period 2 ^[1]	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab
Started	18	9	23
Completed	5	1	9
Not completed	13	8	14
Consent withdrawn by subject	1	1	2
Adverse event, non-fatal	1	2	-
Non-compliance with study drug	-	-	1
Unspecified	-	-	3
Progressive disease	9	3	6
Physician's decision	2	2	2

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: The number of subjects starting the period is accurate as specified

Baseline characteristics

Reporting groups

Reporting group title	Chemotherapy +Avelumab -> Avelumab + Talazoparib
-----------------------	--

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² intravenously(IV) over 3 hours followed by carboplatin area under the concentration (AUC) 5 or 6 IV over 15-60 minutes on Days 1 of each 3 week cycle for 6 cycles along with avelumab 800 mg administered IV on Day 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received avelumab 800 mg administered IV on Days 1, 15 and 29 of each 6-week cycle in combination with talazoparib 0.75 mg self-administered orally once per day. A cycle was defined as 3 weeks (21 days) in the chemotherapy period and 6 weeks (42 days) in the maintenance period, respectively.

Reporting group title	Chemotherapy -> Talazoparib
-----------------------	-----------------------------

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Days 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received talazoparib 0.75 mg self-administered orally once a day, every day of each 6-week cycle.

Reporting group title	Chemotherapy + Bevacizumab -> Bevacizumab
-----------------------	---

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Day 1 of each 3-week cycle for 6 cycles along with Bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle beginning with Cycle 2 for adjuvant subjects, and for neoadjuvant subjects, bevacizumab was given on Day 1 of each 3-week cycle for Cycles 1, 2, 5, and 6. In maintenance period, subjects received bevacizumab 15 mg/kg administered IV on Days 1 and 22 of each 6-week cycle.

Reporting group values	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab
Number of subjects	32	13	34
Age Categorical Units: Subjects			
< 65 years	21	8	20
65 =< 75 years	7	4	9
75 =< 85 years	4	1	5
>= 85 years	0	0	0
Not Reported	0	0	0
Age Continuous Units: years			
arithmetic mean	61.38	58.46	63.29
standard deviation	± 11.32	± 12.67	± 9.83
Sex: Female, Male Units: Subjects			
Female	32	13	34
Male	0	0	0
Race/Ethnicity, Customized Units: Subjects			
Blank or African American	0	0	1
American Indian or Alaska Native	0	0	1
Asian	2	3	7
Native Hawaiian or Other Pacific Islander	0	0	0

White	29	10	24
Other	1	0	1
Unknown	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	6	1	5
Not Hispanic or Latino	26	11	27
Unknown or Not Reported	0	1	2

Reporting group values	Total		
Number of subjects	79		
Age Categorical			
Units: Subjects			
< 65 years	49		
65 =< 75 years	20		
75 =< 85 years	10		
>= 85 years	0		
Not Reported	0		
Age Continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: Subjects			
Female	79		
Male	0		
Race/Ethnicity, Customized			
Units: Subjects			
Blank or African American	1		
American Indian or Alaska Native	1		
Asian	12		
Native Hawaiian or Other Pacific Islander	0		
White	63		
Other	2		
Unknown	0		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	12		
Not Hispanic or Latino	64		
Unknown or Not Reported	3		

End points

End points reporting groups

Reporting group title	Chemotherapy +Avelumab -> Avelumab + Talazoparib
-----------------------	--

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² intravenously(IV) over 3 hours followed by carboplatin area under the concentration (AUC) 5 or 6 IV over 15-60 minutes on Days 1 of each 3 week cycle for 6 cycles along with avelumab 800 mg administered IV on Day 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received avelumab 800 mg administered IV on Days 1, 15 and 29 of each 6-week cycle in combination with talazoparib 0.75 mg self-administered orally once per day. A cycle was defined as 3 weeks (21 days) in the chemotherapy period and 6 weeks (42 days) in the maintenance period, respectively.

Reporting group title	Chemotherapy -> Talazoparib
-----------------------	-----------------------------

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Days 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received talazoparib 0.75 mg self-administered orally once a day, every day of each 6-week cycle.

Reporting group title	Chemotherapy + Bevacizumab -> Bevacizumab
-----------------------	---

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Day 1 of each 3-week cycle for 6 cycles along with Bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle beginning with Cycle 2 for adjuvant subjects, and for neoadjuvant subjects, bevacizumab was given on Day 1 of each 3-week cycle for Cycles 1, 2, 5, and 6. In maintenance period, subjects received bevacizumab 15 mg/kg administered IV on Days 1 and 22 of each 6-week cycle.

Reporting group title	Chemotherapy +Avelumab -> Avelumab + Talazoparib
-----------------------	--

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² intravenously(IV) over 3 hours followed by carboplatin area under the concentration (AUC) 5 or 6 IV over 15-60 minutes on Days 1 of each 3 week cycle for 6 cycles along with avelumab 800 mg administered IV on Day 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received avelumab 800 mg administered IV on Days 1, 15 and 29 of each 6-week cycle in combination with talazoparib 0.75 mg self-administered orally once per day. A cycle was defined as 3 weeks (21 days) in the chemotherapy period and 6 weeks (42 days) in the maintenance period, respectively.

Reporting group title	Chemotherapy -> Talazoparib
-----------------------	-----------------------------

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Days 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received talazoparib 0.75 mg self-administered orally once a day, every day of each 6-week cycle.

Reporting group title	Chemotherapy + Bevacizumab -> Bevacizumab
-----------------------	---

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Day 1 of each 3-week cycle for 6 cycles along with Bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle beginning with Cycle 2 for adjuvant subjects, and for neoadjuvant subjects, bevacizumab was given on Day 1 of each 3-week cycle for Cycles 1, 2, 5, and 6. In maintenance period, subjects received bevacizumab 15 mg/kg administered IV on Days 1 and 22 of each 6-week cycle.

Primary: Progression-Free Survival (Subjects with newly diagnosed advanced ovarian cancer with defects in DDR+)

End point title	Progression-Free Survival (Subjects with newly diagnosed advanced ovarian cancer with defects in DDR+ ^[1])
-----------------	--

End point description:

PFS was defined as the time from randomization to the date of the first documentation of objective progressive disease (PD) or death due to any cause, whichever occurred first. PD: $\geq 20\%$ increase in

sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5mm, appearance of one or more new lesions was considered PD. The analysis population included all randomized subjects. As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study. A total of 104 subjects were screened and 79 subjects completed screening and randomized in the study before study discontinuation, and 76 subjects were treated across 3 treatment arms. As only 11% projected enrollment was met when enrollment stopped, the original study endpoints are no longer applicable and/or feasible.

End point type	Primary
----------------	---------

End point timeframe:

At screening, 9 and 18 weeks after date of randomization, then every 12 weeks thereafter until PD by Blinded Independent Central Review (BICR) regardless of initiation of new anti-cancer therapy

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this endpoint

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[2]	0 ^[3]	0 ^[4]	
Units: months				
median (confidence interval 95%)	(to)	(to)	(to)	

Notes:

[2] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[3] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[4] - Data for this endpoint was not reported as no formal efficacy analyses performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Treatment-Emergent Adverse Events (On-Treatment Period)

End point title	Number of Subjects with Treatment-Emergent Adverse Events (On-Treatment Period)
-----------------	---

End point description:

An adverse event (AE) was any untoward medical occurrence in a study subject administered a product; the event need not necessarily have a causal relationship with the treatment or usage. A serious adverse event was any untoward medical occurrence at any dose that resulted in death, was lifethreatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant

disability/incapacity, resulted in congenital anomaly/birth defect or considered to be an important medical event. An AE was considered TEAE if the event occurred during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment through up to 30 days after minimum last dose of study treatment or start day of new anti-cancer drug therapy minus 1 day. The analysis population included all randomized subjects who received at least 1 dose of study drug (avelumab, talazoparib, bevacizumab, carboplatin, paclitaxel).

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study treatment through up to 30 days after minimum last dose of study treatment or start day of new anti-cancer drug therapy minus 1 day (maximum up to 3.5 years approximately)

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	29	13	34	
Units: Subjects				
Subjects with TEAEs	29	13	34	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With ADA Against Avelumab by Never and Ever Positive Status

End point title	Number of Subjects With ADA Against Avelumab by Never and Ever Positive Status ^[5]
-----------------	---

End point description:

Pre-dose Antidrug antibodies (ADA) samples were collected within 2 hours prior to avelumab dosing and drawn from the contralateral arm of the avelumab infusion. The analysis population included subjects in Arm A (Chemotherapy +Avelumab -> Avelumab + Talazoparib) only, who had at least 1 ADA sample collected. Only avelumab containing Arm (Arm A) was included as the analysis was against avelumab.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 pre-dose of Cycles 1, 2, 3, and 4 in the chemotherapy period and Days 1 and 29 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 10 in the maintenance period. A sample was also collected at the end of treatment/withdrawal.

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reporting statistics for the arms specified.

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib			
Subject group type	Reporting group			
Number of subjects analysed	29			
Units: Subjects				
ADA never-positive	17			
ADA ever-positive	12			

Statistical analyses

No statistical analyses for this end point

Secondary: Pre-dose/trough concentration (Ctrough) for avelumab (chemotherapy period)

End point title	Pre-dose/trough concentration (Ctrough) for avelumab (chemotherapy period) ^[6]
-----------------	---

End point description:

Ctrough was defined as predose concentration during multiple dosing and it was observed directly from data. The analysis population included subjects who had at least 1 concentration above the below limit of quantitation (BLQ) of either avelumab or talazoparib. Only avelumab containing arm (Arm A) was applicable as it was an analysis of avelumab. concentration..Here, "Number of Subjects analyzed" signifies number of subjects evaluable for this endpoint.

End point type Secondary

End point timeframe:

Day 1 of Cycles 1, 2, 3, and 4 in the chemotherapy period (1 cycle = 3 weeks)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point is reporting statistics for the arms specified.

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib			
Subject group type	Reporting group			
Number of subjects analysed	29			
Units: mcg/mL				
median (full range (min-max))				
Cycle 1 Day 1 0H	0.000 (0.00 to 5.61)			
Cycle 2 Day 1 0H	4.370 (0.00 to 10.8)			
Cycle 3 Day 1 0H	6.100 (0.00 to 20.9)			
Cycle 4 Day 1 0H	10.00 (0.686 to 16.1)			

Statistical analyses

No statistical analyses for this end point

Secondary: Pre-dose/trough concentration (Ctrough) for avelumab (maintenance period)

End point title Pre-dose/trough concentration (Ctrough) for avelumab (maintenance period)^[7]

End point description:

Ctrough was defined as predose concentration during multiple dosing and it was observed directly from data. The analysis population included subjects who had at least 1 concentration above the below limit of quantitation (BLQ) of either avelumab or talazoparib. Only avelumab containing arm (Arm A) was applicable as it was an analysis of avelumab. concentration..Here, "Number of Subjects analyzed" signifies number of subjects evaluable for this endpoint.

End point type Secondary

End point timeframe:

Pre-dose on Days 1 and 29 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 10 in the maintenance period (1 cycle = 6 weeks) and at the end of treatment.

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point is reporting statistics for the arms specified.

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib			
Subject group type	Reporting group			
Number of subjects analysed	29			
Units: mcg/mL				
median (full range (min-max))				
Cycle 1 Day 1 0H	3.470 (0.00 to 25.7)			
Cycle 1 Day 29 0H	41.60 (19.5 to 78.0)			
Cycle 2 Day 1 0H	33.90 (25.7 to 63.6)			
Cycle 4 Day 1 0H	28.60 (23.3 to 41.0)			
Cycle 6 Day 1 0H	20.6 (20.6 to 20.6)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cmax for avelumab (chemotherapy period)

End point title	Cmax for avelumab (chemotherapy period) ^[8]
End point description:	Cmax was defined as maximum observed plasma concentration and it was observed directly from data. The analysis population included subjects who had at least 1 concentration above the below limit of quantitation (BLQ) of either avelumab or talazoparib. Only avelumab containing arm (Arm A) was applicable as it was an analysis of avelumab concentration. Here, "Number of Subjects analyzed" signifies number of subjects evaluable for this endpoint.
End point type	Secondary
End point timeframe:	Day 1 of Cycles 1, 2, 3, and 4 in the chemotherapy period (1 cycle = 3 weeks)

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point is reporting statistics for the arms specified.

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib			
Subject group type	Reporting group			
Number of subjects analysed	29			
Units: mcg/mL				
median (full range (min-max))				
Cycle 1 Day 1 1H/End of infusion(EOI)	218.0 (132 to 318)			
Cycle 2 Day 1 1H/End of infusion(EOI)	222.5 (29.8 to 319)			
Cycle 3 Day 1 1H/End of infusion(EOI)	253.0 (157 to 349)			
Cycle 4 Day 1 1H/End of infusion(EOI)	243.0 (139 to 343)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cmax for avelumab (maintenance period)

End point title Cmax for avelumab (maintenance period)^[9]

End point description:

Cmax was defined as maximum observed plasma concentration and it was observed directly from data. The analysis population included subjects who had at least 1 concentration above the below limit of quantitation (BLQ) of either avelumab or talazoparib. Only avelumab containing arm (Arm A) was applicable as it was an analysis of avelumab concentration. Here, "Number of Subjects analyzed" signifies number of subjects evaluable for this endpoint.

End point type Secondary

End point timeframe:

Days 1 and 29 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 10 in the maintenance period (1 cycle = 6 weeks). A sample was also collected at the end of treatment/withdrawal.

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reporting statistics for the arms specified.

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib			
Subject group type	Reporting group			
Number of subjects analysed	29			
Units: mcg/mL				
median (full range (min-max))				
Cycle 1 Day 1 1H/End of infusion(EOI)	227.0 (154 to 282)			
Cycle 1 Day 29 1H/End of infusion(EOI)	279.0 (190 to 485)			
Cycle 2 Day 1 1H/End of infusion(EOI)	222.0 (158 to 289)			
Cycle 4 Day 1 1H/End of infusion(EOI)	225.0 (224 to 226)			
Cycle 6 Day 1 1H/End of infusion(EOI)	219.0 (219 to 219)			

Statistical analyses

No statistical analyses for this end point

Secondary: Ctrough for talazoprib (maintenance period)

End point title Ctrough for talazoprib (maintenance period)^[10]

End point description:

Ctrough was defined as predose concentration during multiple dosing and it was observed directly from data. The analysis population included subjects who had at least 1 concentration above the below limit of quantitation (BLQ) of either avelumab or talazoparib. Only avelumab containing arm (Arm A) was applicable as it was an analysis of avelumab. concentration..Here, "Number of Subjects analyzed" signifies number of subjects evaluable for this endpoint.

End point type Secondary

End point timeframe:

Pre-dose on Days 1, 15 and 29 of Cycle 1

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reporting statistics for the arms specified.

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16	8		
Units: pg/mL				
median (full range (min-max))				
Cycle 1 Day 1	0.000 (0.00 to 0.00)	0.000 (0.00 to 0.00)		
Cycle 1 Day 15	2425 (1920 to 2930)	1343 (865 to 1820)		
Cycle 1 Day 29	2500 (2060 to 6470)	1950 (660 to 3290)		

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (subjects of both DDR+ and unselected DDR status)

End point title Overall Survival (subjects of both DDR+ and unselected DDR status)

End point description:

OS was defined as the time from the date of randomization to the date of death due to any cause. As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study.

A total of 104 subjects were screened and 79 subjects completed screening and randomized in the study before study discontinuation, and 76 subjects were treated across 3 treatment arms. As only 11% projected enrollment was met when enrollment stopped, the original study endpoints are no longer applicable and/or feasible.

End point type Secondary

End point timeframe:

From 9 weeks up to 144 months

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[11]	0 ^[12]	0 ^[13]	
Units: months				
median (confidence interval 95%)	(to)	(to)	(to)	

Notes:

[11] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[12] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[13] - Data for this endpoint was not reported as no formal efficacy analyses performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-Free Survival (subjects of unselected DDR status)

End point title	Progression-Free Survival (subjects of unselected DDR status)
-----------------	---

End point description:

PFS was defined as the time from the date of randomization to the date of the first documentation of PD or death due to any cause, whichever occurred first.

As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study.

A total of 104 subjects were screened and 79 subjects completed screening and randomized in the study before study discontinuation, and 76 subjects were treated across 3 treatment arms. As only 11% projected enrollment was met when enrollment stopped, the original study endpoints are no longer applicable and/or feasible.

End point type	Secondary
----------------	-----------

End point timeframe:

At screening, 9 and 18 weeks after date of randomization, then every 12 weeks thereafter until PD by BICR regardless of initiation of new anti-cancer therapy

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[14]	0 ^[15]	0 ^[16]	
Units: months				
median (confidence interval 95%)	(to)	(to)	(to)	

Notes:

[14] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[15] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[16] - Data for this endpoint was not reported as no formal efficacy analyses performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-Free Survival (subjects of both DDR+ and unselected DDR status)

End point title	Progression-Free Survival (subjects of both DDR+ and unselected DDR status)
-----------------	---

End point description:

PFS was defined as the time from randomization to the date of the first documentation of objective progressive disease (PD) or death due to any cause, whichever occurred first. Subjects were defined as having defective DDR (DDR+) or having intact DDR (DDR-) using a next generation sequencing based assay method.

As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study.

A total of 104 subjects were screened and 79 subjects completed screening and randomized in the study before study discontinuation, and 76 subjects were treated across 3 treatment arms. As only 11% projected enrollment was met when enrollment stopped, the original study endpoints are no longer applicable and/or feasible.

End point type	Secondary
----------------	-----------

End point timeframe:

At screening, 9 and 18 weeks after date of randomization, then every 12 weeks thereafter until PD by BICR regardless of initiation of new anti-cancer therapy

End point values	Chemotherapy + Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[17]	0 ^[18]	0 ^[19]	
Units: months				
median (confidence interval 95%)	(to)	(to)	(to)	

Notes:

[17] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[18] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[19] - Data for this endpoint was not reported as no formal efficacy analyses performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-Free Survival on next-line therapy (subjects of both DDR+ and unselected DDR status)

End point title	Progression-Free Survival on next-line therapy (subjects of both DDR+ and unselected DDR status)
-----------------	--

End point description:

Progression-free survival on next-line therapy (PFS2) was defined as time from the date of randomization to the start of second subsequent treatment after first documentation of PD, or death from any cause, whichever occurred first. Subjects were defined as having defective DDR (DDR+) or having intact DDR (DDR-) using a next generation sequencing based assay method.

As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study.

A total of 104 subjects were screened and 79 subjects completed screening and randomized in the study before study discontinuation, and 76 subjects were treated across 3 treatment arms. As only 11% projected enrollment was met when enrollment stopped, the original study endpoints are no longer applicable and/or feasible.

End point type	Secondary
----------------	-----------

End point timeframe:

From screening until the subject had objective PD on or prior to start of next-line anti-cancer treatment, and started a second subsequent anti-cancer treatment or the subject died.

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[20]	0 ^[21]	0 ^[22]	
Units: months				
median (confidence interval 95%)	(to)	(to)	(to)	

Notes:

[20] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[21] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[22] - Data for this endpoint was not reported as no formal efficacy analyses performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Functional Assessment of Ovarian Symptom Index-18 (FOSI-18) Score

End point title	Functional Assessment of Ovarian Symptom Index-18 (FOSI-18) Score
-----------------	---

End point description:

NFOSI-18 was an ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer. It was specifically designed to be a stand-alone instrument to measure disease-related symptoms, treatment side effects and function/well-being in subjects with ovarian cancer.

The NFOSI-18 has several subscales: disease-related symptoms physical subscale (9 items), disease-related symptoms emotional subscale(1 item), treatment-related side effect subscale (5 items) and functional well-being (3 items). A score of "0" was a severely symptomatic subject and the highest possible score was an asymptomatic subject.

As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study. As only 11% projected enrollment was met when enrollment stopped, the original study endpoints are no longer applicable and/or feasible.

End point type	Secondary
----------------	-----------

End point timeframe:

3 years

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[23]	0 ^[24]	0 ^[25]	
Units: units on a scale				
arithmetic mean (standard deviation)	()	()	()	

Notes:

[23] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[24] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[25] - Data for this endpoint was not reported as no formal efficacy analyses performed.

Statistical analyses

No statistical analyses for this end point

Secondary: PFS per Gynecological Cancer Intergroup criteria (subjects of both

DDR+ and unselected DDR status)

End point title	PFS per Gynecological Cancer Intergroup criteria (subjects of both DDR+ and unselected DDR status)
-----------------	--

End point description:

PFS based on investigator assessment per Gynecological Cancer Intergroup criteria (GCIG) would be assessed incorporating both Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and CA 125. Subjects was defined as having defective DDR (DDR+) or having intact DDR (DDR) using a next generation sequencing based assay method.

As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study.

A total of 104 subjects were screened and 79 subjects completed screening and randomized in the study before study discontinuation, and 76 subjects were treated across 3 treatment arms. As only 11% projected enrollment was met when enrollment stopped, the original study endpoints are no longer applicable and/or feasible.

End point type	Secondary
----------------	-----------

End point timeframe:

From screening until death, end of study, or subject withdrawal of consent, whichever occurred first.

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[26]	0 ^[27]	0 ^[28]	
Units: months				
median (confidence interval 95%)	(to)	(to)	(to)	

Notes:

[26] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[27] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[28] - Data for this endpoint was not reported as no formal efficacy analyses performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Programmed Death Receptor-1 Ligand-1 (PD-L1) Biomarker Expression in Tumor and Immune Cells as Assessed by Immunohistochemistry (IHC) at Baseline

End point title	Programmed Death Receptor-1 Ligand-1 (PD-L1) Biomarker Expression in Tumor and Immune Cells as Assessed by Immunohistochemistry (IHC) at Baseline
-----------------	---

End point description:

The number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and inflammatory cells in regions of interest that were defined by tumor cell morphology and the presence or absence of inflammatory cells.

As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study.

A total of 104 subjects were screened and 79 subjects completed screening and randomized in the study before study discontinuation, and 76 subjects were treated across 3 treatment arms. As only 11% projected enrollment was met when enrollment stopped, the original study endpoints are no longer applicable and/or feasible.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline

End point values	Chemotherapy + Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[29]	0 ^[30]	0 ^[31]	
Units: Percentage of cells staining positive				
median (full range (min-max))	(to)	(to)	(to)	

Notes:

[29] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[30] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[31] - Data for this endpoint was not reported as no formal efficacy analyses performed.

Statistical analyses

No statistical analyses for this end point

Secondary: EuroQol Group 5Dimension 5Level (EQ5D5L) Score

End point title	EuroQol Group 5Dimension 5Level (EQ5D5L) Score
-----------------	--

End point description:

The EuroQol EQ-5D-5L was a 6 item subject-completed questionnaire designed to assess health status in terms of a single index value or utility score. There are 2 components to the EQ-5D-5L, a Health State Profile which had individuals rate their level of problems (none, slight, moderate, severe, extreme/unable) in 5 areas (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), and a Visual Analogue Scale (VAS) in which subjects rate their overall health status from 0 (worst imaginable) to 100 (best imaginable). Overall index scores ranged from 0 to 1, with low scores representing a higher level of dysfunction.

As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study.

As only 11% projected enrollment was met when enrollment stopped, the original study endpoints are no longer applicable and/or feasible.

End point type	Secondary
----------------	-----------

End point timeframe:

3 years

End point values	Chemotherapy + Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[32]	0 ^[33]	0 ^[34]	
Units: units on a scale				
arithmetic mean (standard deviation)	()	()	()	

Notes:

[32] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[33] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[34] - Data for this endpoint was not reported as no formal efficacy analyses performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with mutations in key oncogenes at baseline

End point title	Number of subjects with mutations in key oncogenes at baseline
-----------------	--

End point description:

Determination/estimation of the frequency of mutations (total and non-synonymous) present in baseline tumor derived nucleic acid samples and in baseline circulating tumor DNA.

A total of 104 subjects were screened and 79 subjects completed screening and randomized in the study before study discontinuation, and 76 subjects were treated across 3 treatment arms. As only 11% projected enrollment was met when enrollment stopped, the original study endpoints are no longer applicable and/or feasible.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline

End point values	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy -> Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[35]	0 ^[36]	0 ^[37]	
Units: Subjects				

Notes:

[35] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[36] - Data for this endpoint was not reported as no formal efficacy analyses performed.

[37] - Data for this endpoint was not reported as no formal efficacy analyses performed.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the signing of Informed consent (IC) up to 90 calendar days after the last administration of the investigational product (maximum of 3.5 years). AEs were summarized based on the on-treatment period unless otherwise specified.

Adverse event reporting additional description:

Both non serious AEs and SAEs were recorded on the case report form.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.1
--------------------	------

Reporting groups

Reporting group title	Chemotherapy +Avelumab -> Avelumab + Talazoparib
-----------------------	--

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² intravenously(IV) over 3 hours followed by carboplatin area under the concentration (AUC) 5 or 6 IV over 15-60 minutes on Days 1 of each 3 week cycle for 6 cycles along with avelumab 800 mg administered IV on Day 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received avelumab 800 mg administered IV on Days 1, 15 and 29 of each 6-week cycle in combination with talazoparib 0.75 mg self-administered orally once per day. A cycle was defined as 3 weeks (21 days) in the chemotherapy period and 6 weeks (42 days) in the maintenance period, respectively.

Reporting group title	Chemotherapy + Bevacizumab -> Bevacizumab
-----------------------	---

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Day 1 of each 3-week cycle for 6 cycles along with Bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle beginning with Cycle 2 for adjuvant subjects, and for neoadjuvant subjects, bevacizumab was given on Day 1 of each 3-week cycle for Cycles 1, 2, 5, and 6. In maintenance period, subjects received bevacizumab 15 mg/kg administered IV on Days 1 and 22 of each 6-week cycle.

Reporting group title	Chemotherapy -> Talazoparib
-----------------------	-----------------------------

Reporting group description:

In chemotherapy period, subjects received paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5 or 6 IV over 15-60 minutes on Days 1 of each 3-week cycle for 6 cycles. In maintenance period, subjects received talazoparib 0.75 mg self-administered orally once a day, every day of each 6-week cycle.

Serious adverse events	Chemotherapy +Avelumab -> Avelumab + Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	Chemotherapy -> Talazoparib
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 29 (31.03%)	15 / 34 (44.12%)	4 / 13 (30.77%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Vascular disorders			
Hypertension			

subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Incarcerated hernia			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 29 (3.45%)	2 / 34 (5.88%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	1 / 1	3 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 29 (0.00%)	0 / 34 (0.00%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Anxiety			

subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
C-reactive protein increased			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Muscle strain			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	1 / 29 (3.45%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	1 / 29 (3.45%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	2 / 29 (6.90%)	3 / 34 (8.82%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	1 / 2	3 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Ascites			
subjects affected / exposed	1 / 29 (3.45%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	1 / 29 (3.45%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 29 (3.45%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	1 / 29 (3.45%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 29 (0.00%)	0 / 34 (0.00%)	2 / 13 (15.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 29 (0.00%)	0 / 34 (0.00%)	2 / 13 (15.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Hydronephrosis			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proteinuria			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 34 (0.00%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Urosepsis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 34 (0.00%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Chemotherapy + Avelumab -> Avelumab + Talazoparib	Chemotherapy + Bevacizumab -> Bevacizumab	Chemotherapy -> Talazoparib
Total subjects affected by non-serious adverse events			
subjects affected / exposed	29 / 29 (100.00%)	34 / 34 (100.00%)	13 / 13 (100.00%)
Vascular disorders			
Hot flush			
subjects affected / exposed	3 / 29 (10.34%)	2 / 34 (5.88%)	2 / 13 (15.38%)
occurrences (all)	3	2	2
Flushing			
subjects affected / exposed	2 / 29 (6.90%)	3 / 34 (8.82%)	1 / 13 (7.69%)
occurrences (all)	2	4	3
Deep vein thrombosis			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	1 / 13 (7.69%)
occurrences (all)	0	1	1
Hypertension			
subjects affected / exposed	0 / 29 (0.00%)	11 / 34 (32.35%)	1 / 13 (7.69%)
occurrences (all)	0	21	1
Hypotension			

subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	1 / 34 (2.94%) 1	0 / 13 (0.00%) 0
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	0 / 29 (0.00%)	2 / 34 (5.88%)	0 / 13 (0.00%)
occurrences (all)	0	4	0
Gait disturbance			
subjects affected / exposed	0 / 29 (0.00%)	0 / 34 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	14 / 29 (48.28%)	9 / 34 (26.47%)	6 / 13 (46.15%)
occurrences (all)	17	14	13
Asthenia			
subjects affected / exposed	2 / 29 (6.90%)	3 / 34 (8.82%)	3 / 13 (23.08%)
occurrences (all)	5	5	3
Peripheral swelling			
subjects affected / exposed	0 / 29 (0.00%)	2 / 34 (5.88%)	1 / 13 (7.69%)
occurrences (all)	0	2	1
Pain			
subjects affected / exposed	5 / 29 (17.24%)	2 / 34 (5.88%)	0 / 13 (0.00%)
occurrences (all)	5	2	0
Oedema peripheral			
subjects affected / exposed	0 / 29 (0.00%)	4 / 34 (11.76%)	1 / 13 (7.69%)
occurrences (all)	0	5	1
Malaise			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	1 / 13 (7.69%)
occurrences (all)	0	1	1
Influenza like illness			
subjects affected / exposed	0 / 29 (0.00%)	0 / 34 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	5 / 29 (17.24%)	4 / 34 (11.76%)	1 / 13 (7.69%)
occurrences (all)	7	4	1
Temperature intolerance			

subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	1 / 13 (7.69%)
occurrences (all)	0	1	1
Hypersensitivity			
subjects affected / exposed	0 / 29 (0.00%)	3 / 34 (8.82%)	0 / 13 (0.00%)
occurrences (all)	0	3	0
Drug hypersensitivity			
subjects affected / exposed	0 / 29 (0.00%)	0 / 34 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	2 / 29 (6.90%)	1 / 34 (2.94%)	0 / 13 (0.00%)
occurrences (all)	2	1	0
Vaginal discharge			
subjects affected / exposed	0 / 29 (0.00%)	2 / 34 (5.88%)	0 / 13 (0.00%)
occurrences (all)	0	3	0
Vulvovaginal pruritus			
subjects affected / exposed	2 / 29 (6.90%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences (all)	2	0	0
Vulvovaginal pain			
subjects affected / exposed	0 / 29 (0.00%)	0 / 34 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Vulvovaginal burning sensation			
subjects affected / exposed	0 / 29 (0.00%)	0 / 34 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Epistaxis			
subjects affected / exposed	2 / 29 (6.90%)	3 / 34 (8.82%)	0 / 13 (0.00%)
occurrences (all)	2	3	0
Dyspnoea			
subjects affected / exposed	7 / 29 (24.14%)	5 / 34 (14.71%)	3 / 13 (23.08%)
occurrences (all)	10	8	4
Cough			

subjects affected / exposed occurrences (all)	6 / 29 (20.69%) 8	5 / 34 (14.71%) 7	3 / 13 (23.08%) 3
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	4 / 34 (11.76%) 4	0 / 13 (0.00%) 0
Pleural effusion subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	0 / 34 (0.00%) 0	0 / 13 (0.00%) 0
Upper-airway cough syndrome subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	3 / 34 (8.82%) 3	2 / 13 (15.38%) 2
Depression subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	5 / 29 (17.24%) 5	5 / 34 (14.71%) 5	2 / 13 (15.38%) 2
Mental status changes subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	3 / 34 (8.82%) 6	1 / 13 (7.69%) 1
Amylase increased subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0
Aspartate aminotransferase increased			

subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 34 (5.88%) 5	2 / 13 (15.38%) 2
Blood corticotrophin increased subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Lipase increased subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 34 (5.88%) 2	1 / 13 (7.69%) 1
Neutrophil count decreased subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 9	3 / 34 (8.82%) 6	3 / 13 (23.08%) 12
Platelet count decreased subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 10	3 / 34 (8.82%) 9	0 / 13 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	0 / 34 (0.00%) 0	0 / 13 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 4	1 / 34 (2.94%) 1	1 / 13 (7.69%) 8
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	1 / 34 (2.94%) 1	0 / 13 (0.00%) 0
Infusion related reaction subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 4	2 / 34 (5.88%) 3	2 / 13 (15.38%) 2
Foot fracture subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Fall subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	1 / 34 (2.94%) 1	1 / 13 (7.69%) 1
Vulvovaginal injury			

subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Cardiac disorders			
Atrial fibrillation subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	0 / 34 (0.00%) 0	0 / 13 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 3	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0
Nervous system disorders			
Cognitive disorder subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Hypoaesthesia subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 5	2 / 34 (5.88%) 2	2 / 13 (15.38%) 2
Headache subjects affected / exposed occurrences (all)	5 / 29 (17.24%) 5	10 / 34 (29.41%) 10	2 / 13 (15.38%) 2
Dysgeusia subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Dizziness subjects affected / exposed occurrences (all)	8 / 29 (27.59%) 11	5 / 34 (14.71%) 5	4 / 13 (30.77%) 4
Neuropathy peripheral subjects affected / exposed occurrences (all)	8 / 29 (27.59%) 9	12 / 34 (35.29%) 15	1 / 13 (7.69%) 2
Paraesthesia subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	3 / 34 (8.82%) 4	1 / 13 (7.69%) 1
Taste disorder subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	1 / 34 (2.94%) 1	1 / 13 (7.69%) 1
Restless legs syndrome			

subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0
Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 3	3 / 34 (8.82%) 3	3 / 13 (23.08%) 6
Blood and lymphatic system disorders			
Leukopenia subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 3	4 / 34 (11.76%) 22	1 / 13 (7.69%) 4
Anaemia subjects affected / exposed occurrences (all)	12 / 29 (41.38%) 25	14 / 34 (41.18%) 22	3 / 13 (23.08%) 17
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Neutropenia subjects affected / exposed occurrences (all)	12 / 29 (41.38%) 38	14 / 34 (41.18%) 41	5 / 13 (38.46%) 10
Splenomegaly subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Thrombocytopenia subjects affected / exposed occurrences (all)	8 / 29 (27.59%) 23	2 / 34 (5.88%) 7	0 / 13 (0.00%) 0
Ear and labyrinth disorders			
Vertigo subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 34 (5.88%) 2	1 / 13 (7.69%) 1
Eye disorders			
Visual field defect subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Vision blurred subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Lacrimation increased			

subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	1 / 34 (2.94%) 1	1 / 13 (7.69%) 1
Abdominal distension subjects affected / exposed occurrences (all)	4 / 29 (13.79%) 4	4 / 34 (11.76%) 7	0 / 13 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	8 / 29 (27.59%) 10	7 / 34 (20.59%) 9	3 / 13 (23.08%) 3
Abdominal pain lower subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	0 / 34 (0.00%) 0	1 / 13 (7.69%) 2
Abdominal pain upper subjects affected / exposed occurrences (all)	4 / 29 (13.79%) 5	1 / 34 (2.94%) 1	1 / 13 (7.69%) 1
Constipation subjects affected / exposed occurrences (all)	9 / 29 (31.03%) 11	12 / 34 (35.29%) 4	2 / 13 (15.38%) 3
Diarrhoea subjects affected / exposed occurrences (all)	11 / 29 (37.93%) 11	11 / 34 (32.35%) 21	3 / 13 (23.08%) 3
Dry mouth subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Dyspepsia subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 4	1 / 34 (2.94%) 1	2 / 13 (15.38%) 2
Dysphagia subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Flatulence subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 3	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0

Gingival bleeding subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	12 / 29 (41.38%) 22	14 / 34 (41.18%) 16	3 / 13 (23.08%) 6
Oral pain subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	4 / 29 (13.79%) 4	7 / 34 (20.59%) 11	2 / 13 (15.38%) 2
Stomatitis subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 4	3 / 34 (8.82%) 4	2 / 13 (15.38%) 4
Skin and subcutaneous tissue disorders			
Erythema subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 3	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Dry skin subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0
Alopecia subjects affected / exposed occurrences (all)	12 / 29 (41.38%) 13	10 / 34 (29.41%) 11	7 / 13 (53.85%) 8
Night sweats subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	1 / 34 (2.94%) 2	0 / 13 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	3 / 34 (8.82%) 4	0 / 13 (0.00%) 0
Rash subjects affected / exposed occurrences (all)	4 / 29 (13.79%) 5	3 / 34 (8.82%) 3	2 / 13 (15.38%) 3
Renal and urinary disorders			

Proteinuria			
subjects affected / exposed	0 / 29 (0.00%)	11 / 34 (32.35%)	0 / 13 (0.00%)
occurrences (all)	0	36	0
Haematuria			
subjects affected / exposed	0 / 29 (0.00%)	1 / 34 (2.94%)	1 / 13 (7.69%)
occurrences (all)	0	2	1
Dysuria			
subjects affected / exposed	5 / 29 (17.24%)	0 / 34 (0.00%)	1 / 13 (7.69%)
occurrences (all)	5	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	11 / 29 (37.93%)	11 / 34 (32.35%)	4 / 13 (30.77%)
occurrences (all)	16	13	7
Back pain			
subjects affected / exposed	4 / 29 (13.79%)	5 / 34 (14.71%)	1 / 13 (7.69%)
occurrences (all)	6	8	1
Pain in extremity			
subjects affected / exposed	2 / 29 (6.90%)	5 / 34 (14.71%)	1 / 13 (7.69%)
occurrences (all)	2	7	1
Myalgia			
subjects affected / exposed	8 / 29 (27.59%)	3 / 34 (8.82%)	2 / 13 (15.38%)
occurrences (all)	14	7	2
Muscle spasms			
subjects affected / exposed	2 / 29 (6.90%)	2 / 34 (5.88%)	0 / 13 (0.00%)
occurrences (all)	2	2	0
Flank pain			
subjects affected / exposed	2 / 29 (6.90%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences (all)	2	0	0
Bone pain			
subjects affected / exposed	1 / 29 (3.45%)	2 / 34 (5.88%)	0 / 13 (0.00%)
occurrences (all)	1	2	0
Infections and infestations			
Fungal infection			
subjects affected / exposed	1 / 29 (3.45%)	0 / 34 (0.00%)	1 / 13 (7.69%)
occurrences (all)	1	0	1
Folliculitis			

subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Herpes zoster subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	1 / 34 (2.94%) 1	1 / 13 (7.69%) 1
Nasopharyngitis subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 3	2 / 34 (5.88%) 2	1 / 13 (7.69%) 1
Pneumonia subjects affected / exposed occurrences (all)	5 / 29 (17.24%) 5	0 / 34 (0.00%) 0	0 / 13 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0
Tooth abscess subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	1 / 34 (2.94%) 1	1 / 13 (7.69%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	4 / 29 (13.79%) 7	7 / 34 (20.59%) 11	1 / 13 (7.69%) 1
Vaginal infection subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	0 / 34 (0.00%) 0	1 / 13 (7.69%) 1
Metabolism and nutrition disorders			
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	2 / 34 (5.88%) 2	0 / 13 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 3	3 / 34 (8.82%) 3	2 / 13 (15.38%) 2
Dehydration subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2	3 / 34 (8.82%) 3	2 / 13 (15.38%) 2

Vitamin D deficiency			
subjects affected / exposed	2 / 29 (6.90%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences (all)	2	0	0
Hyponatraemia			
subjects affected / exposed	0 / 29 (0.00%)	5 / 34 (14.71%)	0 / 13 (0.00%)
occurrences (all)	0	7	0
Hypomagnesaemia			
subjects affected / exposed	2 / 29 (6.90%)	5 / 34 (14.71%)	1 / 13 (7.69%)
occurrences (all)	2	12	1
Hypokalaemia			
subjects affected / exposed	4 / 29 (13.79%)	3 / 34 (8.82%)	1 / 13 (7.69%)
occurrences (all)	8	4	1
Hypocalcaemia			
subjects affected / exposed	2 / 29 (6.90%)	0 / 34 (0.00%)	0 / 13 (0.00%)
occurrences (all)	2	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 June 2019	<p>The JAVELIN Ovarian 100 study (B9991010) was stopped due to futility of efficacy at a planned interim analysis, and therefore, the Sponsor decided to stop enrollment in the JAVELIN Ovarian PARP 100 study (B9991030). On 19 March 2019, a Dear Investigator Letter was issued to notify the investigational sites that no new subjects could be screened or randomized.</p> <p>Subjects who remain in the study will continue receiving investigational products according to their randomized treatment assignment and will be monitored for appropriate safety assessments until treatment discontinuation.</p> <p>The purpose of protocol amendment 2 was to reduce study-specific procedure assessments (ie, efficacy, physical examination, electrocardiogram, ePROs and tumor assessments, PK and Biomarkers) for the ongoing subjects.</p> <p>The original schedule of activities(SOA) was replaced by a new SOA. The study objectives and endpoints in Section 2 were no longer applicable and/or feasible. The below assessments in section (Section 7) including Pharmacokinetic (Avelumab and Talazoparib); immunogenicity; Biomarker and Pharmacodynamic; Tumor Tissue Sample; Banked Biospecimens; Tumor Response Assessments including scans and Subject Reported Outcomes were no longer collected. A clarification was also included in the Data Analysis/Statistical Methods section(Section 9) to make the analysis fit for purpose.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

As only 11% projected enrollment was met prior to the study discontinuation, the original study endpoints are no longer applicable and/or feasible, only the Safety, PK and Immunogenicity Analysis were done and these data are included in this report.

Notes: